{"id":"NCT02066129","sponsor":"Milton S. Hershey Medical Center","briefTitle":"Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations","officialTitle":"Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2017-04-21","completion":"2017-04-21","firstPosted":"2014-02-19","resultsPosted":"2018-07-11","lastUpdate":"2018-07-11"},"enrollment":254,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Fluticasone 44 mcg","otherNames":["Flovent® 44 mcg"]},{"type":"DRUG","name":"Fluticasone 220 mcg","otherNames":["Flovent® 220 mcg"]}],"arms":[{"label":"Fluticasone 44 mcg","type":"ACTIVE_COMPARATOR"},{"label":"Fluticasone 220 mcg","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of severe asthma exacerbations treated with oral corticosteroids.","primaryOutcome":{"measure":"Asthma Exacerbations","timeFrame":"end of 48 week treatment period","effectByArm":[{"arm":"Fluticasone 44 mcg","deltaMin":0.37,"sd":null},{"arm":"Fluticasone 220 mcg","deltaMin":0.48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["39510322","37003356","29504498"],"seeAlso":["http://asthmanetresearch.org/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":127},"commonTop":["Acute nasopharyngitis","Allergic rhinitis","Cough","Acute asthma attack","Fever"]}}